Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBT (2020 - 2025)

Rapid Micro Biosystems' EBT history spans 6 years, with the latest figure at -$12.5 million for Q4 2025.

  • On a quarterly basis, EBT fell 29.02% to -$12.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.1 million, a 0.46% change, with the full-year FY2025 number at -$47.1 million, changed 0.46% from a year prior.
  • EBT hit -$12.5 million in Q4 2025 for Rapid Micro Biosystems, down from -$11.5 million in the prior quarter.
  • Over the last five years, EBT for RPID hit a ceiling of -$9.7 million in Q4 2024 and a floor of -$25.0 million in Q3 2021.
  • Historically, EBT has averaged -$14.1 million across 5 years, with a median of -$13.4 million in 2023.
  • Biggest five-year swings in EBT: tumbled 195.64% in 2021 and later soared 34.59% in 2022.
  • Tracing RPID's EBT over 5 years: stood at -$14.6 million in 2021, then decreased by 12.83% to -$16.4 million in 2022, then skyrocketed by 32.09% to -$11.2 million in 2023, then increased by 13.34% to -$9.7 million in 2024, then fell by 29.02% to -$12.5 million in 2025.
  • Business Quant data shows EBT for RPID at -$12.5 million in Q4 2025, -$11.5 million in Q3 2025, and -$11.8 million in Q2 2025.